Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP379403.RAcnPrTEI9D7eA3p3TmrLu0r9YQcvSD1EW4OwRIjYfIyo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP379403.RAcnPrTEI9D7eA3p3TmrLu0r9YQcvSD1EW4OwRIjYfIyo130_assertion type Assertion NP379403.RAcnPrTEI9D7eA3p3TmrLu0r9YQcvSD1EW4OwRIjYfIyo130_head.
- NP379403.RAcnPrTEI9D7eA3p3TmrLu0r9YQcvSD1EW4OwRIjYfIyo130_assertion description "[Moreover, PRK1 activates AR even in the presence of the AR antagonist cyproterone acetate that is used in the clinical management of prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP379403.RAcnPrTEI9D7eA3p3TmrLu0r9YQcvSD1EW4OwRIjYfIyo130_provenance.
- NP379403.RAcnPrTEI9D7eA3p3TmrLu0r9YQcvSD1EW4OwRIjYfIyo130_assertion evidence source_evidence_literature NP379403.RAcnPrTEI9D7eA3p3TmrLu0r9YQcvSD1EW4OwRIjYfIyo130_provenance.
- NP379403.RAcnPrTEI9D7eA3p3TmrLu0r9YQcvSD1EW4OwRIjYfIyo130_assertion SIO_000772 12514133 NP379403.RAcnPrTEI9D7eA3p3TmrLu0r9YQcvSD1EW4OwRIjYfIyo130_provenance.
- NP379403.RAcnPrTEI9D7eA3p3TmrLu0r9YQcvSD1EW4OwRIjYfIyo130_assertion wasDerivedFrom befree-2016 NP379403.RAcnPrTEI9D7eA3p3TmrLu0r9YQcvSD1EW4OwRIjYfIyo130_provenance.
- NP379403.RAcnPrTEI9D7eA3p3TmrLu0r9YQcvSD1EW4OwRIjYfIyo130_assertion wasGeneratedBy ECO_0000203 NP379403.RAcnPrTEI9D7eA3p3TmrLu0r9YQcvSD1EW4OwRIjYfIyo130_provenance.